Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified ...

Recently, the company reported that the European Medicines Agency (EMA) has accepted ANAVEX 2-73 application for early Alzheimer's disease, which could lead to a commercial launch in 2025.

Taxi and ambulance drivers have lower death rates from Alzheimer’s than hundreds of other professions, pointing to a potential link between memory-intensive jobs and dementia risk, a new study ...

Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementSubmission based on ...

Anavex (AVXL) Life Sciences announced that the European Medicines Agency ... an investigational drug for the treatment of Alzheimer’s disease. The Company is looking forward to working with ...